Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1879-1885

  Blumenschein Jr , George R ^a   Khuri, Fadlo R ^b   Von Pawel, Joachim ^b   Gatzemeier, Ulrich ^b   Miller Jr , Wilson H ^b   Jotte, Robert M ^b   Le Treut, Jacques ^b   Sun, Show Li ^b   Zhang, Jinkun K ^b   Dziewanowska, Zofia E ^b   Negro Vilar, Andres ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEXAROTENE; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; CANCER TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTRIGLYCERIDEMIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PACLITAXEL; SURVIVAL ANALYSIS; TETRAHYDRONAPHTHALENES;

EID: 42949179105     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.2689     Document Type: Article

References (16)

1. Brabender J, Danenberg KD, Metzger R, et al: The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 8:438-443, 2002
2. Boehm MF, McClurg MR, Pathirana C, et al: Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties. J Med Chem 37:408-414, 1994
3. Apfel R, Benbrook D, Lernhardt E, et al: A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14:7025-7035, 1994
4. Yen W-C, Corpuz MR, Prudente RY, et al: A selective retinoid x receptor-agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 10:8656-8664, 2004
5. Miller VA, Benedetti FM, Rigas JR, et al: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15:790-795, 1997
6. Rizvi NA, Marshall JL, Dahut W, et al: A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664, 1999
7. Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637, 2001
8. Ramlau R, Zatloukal P, Jassem J, et al: Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26:1886-1892, 2008
9. Rizvi N, Hawkins MJ, Eisenberg PD, et al: Placebo-controlled trial of bexarotene, a retinoid X receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2:210-215, 2001
10. Rizvi N, Miller WH Jr, Aisner J, et al: Retinoid-X-receptor agonist, bexarotene (Targretin capsules), in a phase I-II trial with carboplatin and paclitaxel in patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC). In: Proc ASCO 2002 Molecular Therapeutics Symposium, November 8-10, 2002, San Diego, CA (A100198)
11. Edelman MJ, Smith R, Hausner P, et al: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 23:5774-5778, 2005
12. Govindan R, Crowley J, Schwartzberg L, et al: Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol 24:4848-4854, 2006
13. Yocum RC, Miller VA, Warrell RP, et al: Long-term follow-up of patients with advanced non-small cell lung cancer treated with oral bexarotene. Proc Am Soc Clin Oncol 20, 2001 (abstr 2855)
14. Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: Focus on bexarotene. Oncologist 10:22-33, 2005
15. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (suppl; abstr 4)
16. Rigas JR, Dragnev KH, Petty WJ, et al: A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC). J Clin Oncol 23:654s, 2005 (suppl; abstr 7136)